All In Biotech

Drug Trial Radar · NCT06333951

Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

49

Actual

Start

Sep 17, 2024

Primary completion

Oct 31, 2026

Study completion Nov 30, 2026

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of Anvumetostat administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors.

Conditions

  • Thoracic Tumors
  • Non-small Cell Lung Cancer

Interventions

  • AnvumetostatDrug

    Administered PO

  • CarboplatinDrug

    Administered IV

  • PaclitaxelDrug

    Administered IV

  • PembrolizumabDrug

    Administered IV

  • PemetrexedDrug

    Administered IV

  • SotorasibDrug

    Administered PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose Limiting Toxicities (DLT)Time frame: Up to approximately 21 days
  2. Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE)Time frame: Up to approximately 3 years
  3. Number of Participants Experiencing Serious Adverse Events (SAE)Time frame: Up to approximately 3 years

Locations

83 sites in 20 countries. Site status is shown where the registry gives one.

  • Comprehensive Blood and Cancer Center

    Bakersfield, California

  • City of Hope National Medical Center

    Duarte, California

  • City of Hope Orange County Lennar Foundation Cancer Center

    Duarte, California

  • Translational Research in Oncology US Inc, Trio Central Pharmacy

    Los Angeles, California

  • University of California Irvine

    Orange, California

  • University of California Los Angeles

    Santa Monica, California

  • Rocky Mountain Cancer Centers

    Denver, Colorado

  • Eastern Connecticut Hematology and Oncology Associates

    Norwich, Connecticut

  • HealthPartners Institute

    Saint Paul, Minnesota

  • Saint Lukes Hospital of Kansas City

    Kansas City, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Roswell Park Cancer Institute

    Buffalo, New York

  • New York University Grossman School of Medicine

    New York, New York

  • Perlmutter Cancer Center at New York University Langone Hospital----Long Island

    New York, New York

  • Upstate University Hospital

    Syracuse, New York

  • Hightower Clinical

    Oklahoma City, Oklahoma

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • University of Tennessee Medical Center Knoxville

    Knoxville, Tennessee

  • United States Oncology Regulatory Affairs Corporate Office

    Nashville, Tennessee

  • Texas Oncology - Dallas Fort Worth

    Dallas, Texas

  • US Oncology Research Investigational Products Center

    Dallas, Texas

  • Oncology Consultants Cancer Center

    Houston, Texas

  • Texas Oncology Northeast Texas

    Tyler, Texas

  • Virginia Cancer Specialists PC

    Fairfax, Virginia

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • Cemic

    Ciudad Autonoma Buenos Aires, Argentina

  • Instituto Argentino de Diagnóstico y Tratamiento

    Ciudad Automona de Buenos Aires, Buenos Aires, Argentina

  • Hospital Universitario Austral

    Pilar, Buenos Aires, Argentina

  • Orange Health Service

    Orange, New South Wales, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • Medizinische Universitaet Graz

    Graz, Austria

  • Medizinische Universitaet Innsbruck

    Innsbruck, Austria

  • Centre Hospitalier Universitaire de Liege - Sart Tilman

    Liège, Belgium

  • Instituto Cancer Sao Paulo Icesp

    São Paulo, Brazil

  • Oncosite Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, Brazil

  • Cipo - Centro Integrado de Pesquisa em Oncologia

    Porto Alegre, Rio Grande do Sul, Brazil

  • Fund Faculdade Regional Med Sao Jose Rio Preto

    São José do Rio Preto, São Paulo, Brazil

  • Beneficencia Portuguesa de Sao Paulo - Bp

    São Paulo, São Paulo, Brazil

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

Showing 40 of 83 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.